Related Experiment Video
Updated: Jun 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Treatment of systemic autoimmune and inflammatory diseases with rituximab]
Guillaume Bussone1, Eric Hachulla, Jean Sibilia
1Université Paris Descartes, Pôle de médecine interne, Centre de référence pour les vascularites nécrosantes et la sclérodermie systémique, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, F-75679 Paris Cedex 14, France.
Rituximab is a chimeric monoclonal antibody that targets CD20 antigen at the surface of B lymphocytes. The efficacy of rituximab in patients with rheumatoid arthritis has been demonstrated in 3 randomized controlled trials. Rituximab is now used in a wide range of systemic autoimmune and inflammatory diseases, as it is well tolerated and efficient. Adverse events are scarce, consisting mainly in reactions during infusion and infectious complications that are favoured by the association of rituximab therapy with other immunosuppressants. Relapses of the disease are common around six months after rituximab infusion. The response to retreatment with rituximab is usually the same that was obtained after the first course of treatment.
Rituximab is a chimeric monoclonal antibody that targets CD20 antigen at the surface of B lymphocytes. The efficacy of rituximab in patients with rheumatoid arthritis has been demonstrated in 3 randomized controlled trials. Rituximab is now used in a wide range of systemic autoimmune and inflammatory diseases, as it is well tolerated and efficient. Adverse events are scarce, consisting mainly in reactions during infusion and infectious complications that are favoured by the association of rituximab therapy with other immunosuppressants. Relapses of the disease are common around six months after rituximab infusion. The response to retreatment with rituximab is usually the same that was obtained after the first course of treatment.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Rheumatic Heart Disease III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids